A carregar...
A phase II study of bevacizumab and erlotinib after radiation and temozolomide in MGMT unmethylated GBM patients
Survival for glioblastoma (GBM) patients with an unmethyated MGMT promoter in their tumor is generally worse than methylated MGMT tumors, as temozolomide (TMZ) response is limited. How to better treat patients with unmethylated MGMT is unknown. We performed a trial combining erlotinib and bevacizuma...
Na minha lista:
| Publicado no: | J Neurooncol |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4826294/ https://ncbi.nlm.nih.gov/pubmed/26476729 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11060-015-1958-z |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|